MDxHealth’s molecular diagnostic solutions address a significant unmet medical need for timely, actionable information that addresses the challenges of the current standard of care for diagnosing prostate cancer. Our tests help identify patients at increased risk for aggressive prostate cancer, thereby aiding in the selection of men for prostate biopsy.

Science &

MDxHealth has a proprietary portfolio of biomarkers and bioinformatic technologies from which it develops and commercializes state-of-the-art diagnostic, prognostic and predictive tests for urologic oncology.